Home › Acute Kidney Injury › NCT07556107

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study

Who can join

Ages 18 and older · All sexes

Inclusion criteria

1. Hospitalized or being hospitalized.
2. Age \>/=18 yr old.
3. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.
4. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).
5. Consenting/enrollment will not clinically significantly delay abx administration.
6. Baseline and \>/=1 prior Scr available (within 1 yr).
7. Pt or LAR able to provide IC. Exclusion criteria

1\. AKI (\>/=moderate) (KDIGO stage 2-3) (Scr increase \>/=2-fold from chronic BL) (Scr based).

2\. CKD (\>/=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR \</=44 mL/min/1.73M2) (Scr based).

3\. Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints.

About the study

The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.

What is being tested

• Piperacillin + Tazobactam (drug)
• meropenem (drug)

Sponsor: Bassett Healthcare · Participants: 852 · Started: Aug 17, 2026

Contact the study team

• Jennifer Victory, RN, CCRC · Phone: 607-547-6965

Official record on ClinicalTrials.gov — NCT07556107

Locations in the U.S.

Conditions

• Acute Kidney Injury
• Sepsis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.